Holen Sie sich die Stockscreener-App
2.095
3.47%
-0.065
Schlusskurs vom Vortag:
$2.16
Offen:
$2.14
24-Stunden-Volumen:
297.08K
Relative Volume:
0.24
Marktkapitalisierung:
$169.20M
Einnahmen:
$52.74M
Nettoeinkommen (Verlust:
$-6.60M
KGV:
-24.79
EPS:
-0.0845
Netto-Cashflow:
$-13.63M
1W Leistung:
-6.50%
1M Leistung:
-30.73%
6M Leistung:
+1.21%
1J Leistung:
-15.93%
1-Tages-Spanne:
$2.06
$2.14
1-Wochen-Bereich:
$2.03
$2.24
52-Wochen-Spanne:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.10 | 174.03M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
455.43 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.53 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.68 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Volume Summary: Will Protalix BioTherapeutics Inc benefit from rising consumer demandPortfolio Risk Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Analyst Downgrade: Should I add Protalix BioTherapeutics Inc stock to my portfolio2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX) - Seeking Alpha
Zacks Research Has Bullish Estimate for PLX FY2026 Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for PLX Earnings - MarketBeat
Can Protalix BioTherapeutics Inc lead its sector in growth2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
If You Invested $1,000 in Protalix Biother (PLX) - Stock Titan
A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance - Sahm
Research Analysts Issue Forecasts for PLX FY2026 Earnings - MarketBeat
Stock Market Recap: Is Cirrus Logic Inc forming a bullish divergenceRate Hike & High Win Rate Trade Alerts - baoquankhu1.vn
PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus
Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlig - GuruFocus
PLX: 2025 Full Year Results - Yahoo Finance
Protalix BioTherapeutics (PLX) Misses Earnings Estimates, Projec - GuruFocus
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Finviz
Protalix: Overview of Fourth Quarter Financial Results - Bitget
Protalix (PLX) 2025 10-K details Elfabrio expansion and PRX-115 gout program - Stock Titan
Protalix BioTherapeutics 2025 Annual Report: Innovative Plant Cell-Based Therapeutics, Pipeline, Intellectual Property, and Regulatory Overview - Minichart
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 By Investing.com - Investing.com South Africa
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Yahoo Finance
PLX: EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position - TradingView
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
Recap Report: Can Protalix BioTherapeutics Inc keep up with sector leaders2026 Technical Overview & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Protalix BioTherapeutics Financial Results: Quarterly & Annual ReportNews and Statistics - IndexBox
Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net Loss - TradingView
PLX: 2025 revenue reached $52.7M with a net loss of $6.6M as R&D spending increased sharply - TradingView
Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results - TradingView
Protalix: Q4 Earnings Snapshot - marketscreener.com
PLX: 2025 net loss of $6.6M on $52.7M revenue; 2026 revenue outlook $78–83M with pipeline progress - TradingView
Protalix reports FY2025 results: $52.7M revenue, $6.6M net loss, Q2 2026 EU dosing approval - TradingView
Protalix (PLX) swings to 2025 net loss as R&D spend climbs and assets grow - Stock Titan
Earnings Preview: PLX to Report Financial Results Pre-market on March 18 - 富途牛牛
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Can Protalix BioTherapeutics Inc sustain its profitabilityMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Rare-disease drug maker Protalix sets 2025 financial results call for March 18 - Stock Titan
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive Investors
European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults - Minichart
EC approves new Elfabrio dosing regimen - The Pharma Letter
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Proactive Investors
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance Indicators - Markets Mojo
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Protalix Gains EU Approval for Extended Elfabrio Dosing - TipRanks
Protalix: European Commission approves 2 mg/kg every-4-weeks dosing for Elfabrio - TradingView
EU approves new Elfabrio dosing; Protalix (NYSE: PLX) earns $25M - Stock Titan
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio - marketscreener.com
European Commission Approves New Dosing for Protalix (PLX) Elfab - GuruFocus
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):